Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug 19;8(3):252-6.
doi: 10.5539/gjhs.v8n3p252.

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia

Bijan Keikhaei  1 , Homayon Yousefi, Mohammad Bahadoram
Affiliations

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia

Bijan Keikhaei et al. Glob J Health Sci. .

Abstract

Background & aim: it is well known that hydroxyurea impacts on clinical and hematologic indices in sickle cell disease (SCD), we aimed to evaluate the effect of hydroxyurea on clinical and hematological improvement of sickle cell anemia.

Methods & materials: In this cohort study 48 patients with sickle cell disease were enrolled and pain crisis, severity of pain, acute chest syndrome, the number of hospitalization, the rate of transfusion, spleen size, total Hb, HbF levels, MCV, MCH were compared before and after treatment with HU 10 mg/kg/day/for one year.

Results: In patients with Sickle cell disease Hu significantly decreased the rate of transfusion, hospitalization, spleen size and significantly increased Hb, RBC indices and HbF. Furthermore, we did not find any remarkable adverse effect related to HU during the one year follow up in patients.

Conclusion: We demonstrated that in the course of one year hydroxyurea 10 mg/kg/day can significantly increase HbF, total hemoglobin and RBC indices without any notable side effect in patients with SCD.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

The authors declare that there is no conflict of interests regarding the publication of this paper.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Agrawal R. K, Patel R. K, Shah V, Nainiwal L, Trivedi B. Hydroxyurea in sickle cell disease: drug review. Indian J Hematol Blood Transfus. 2014;30(2):91–96. http://dx.doi.org/10.1007/s12288-013-0261-4 . - PMC - PubMed
    1. Bain B. J. Neonatal/newborn haemoglobinopathy screening in Europe and Africa. J Clin Pathol. 2009;62(1):53–56. http://dx.doi.org/10.1136/jcp.2008.060624 . - PubMed
    1. Bavarsad Shahripour R, Mortazavi M. M, Barlinn K, Keikhaei B, Mousakhani H, Azarpazhooh M. R, Alexandrov A. V. Can STOP Trial Velocity Criteria Be Applied to Iranian Children with Sickle Cell Disease? J Stroke. 2014;16(2):97–101. http://dx.doi.org/10.5853/jos.2014.16.2.97 . - PMC - PubMed
    1. Booth C, Inusa B, Obaro S. K. Infection in sickle cell disease: A review. Int J Infect Dis. 2010;14(1):e2–e12. http://dx.doi.org/10.1016/j.ijid.2009.03.010 . - PubMed
    1. Cokic V. P, Smith R. D, Beleslin-Cokic B. B, Njoroge J. M, Miller J. L, Gladwin M. T, Schechter A. N. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest. 2003;111(2):231–239. http://dx.doi.org/10.1172/JCI200316672 . - PMC - PubMed

Publication types